Navigation Links
Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
Date:2/5/2008

mitted a New Drug Application (NDA) to the FDA for the approval of its lead AzoneTS-based product candidate, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.

Forward-Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements regarding Echo's development plans, objectives, expectations and intentions, including, without limitation, statements regarding the Company's Symphony and AzoneTS product candidates. Factors that could adversely affect Echo's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Echo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

Investor Relations Contacts:

Patrick T. Mooney, M.D.

Chairman & CEO

Echo Therapeutics

508-530-0329

Lilian Stern

Stern Investor Relations

212-362-1200


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
2. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Taligen Therapeutics Secures Series B Financing
5. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
7. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
8. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
9. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 Berkshire Corporation, the world ... announce the release of the ValuSeal® IonX™ cleanroom ... contamination containment in critical processing applications. , Recommended ... cleanroom environments, ValuSeal® IonX™ is a laser sealed ... that continues Berkshire’s innovative focus on meeting new ...
(Date:10/25/2014)... LONDON , October 24, 2014 ... CytRx Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals ... (NASDAQ: ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 23, 2014, ended on a positive ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution ... pain management and clinical markets. The software increases the ... allowing users to highlight and review results that are ... analysts to filter results by group or based on ... the need to sift through analytes of no interest. ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2
... 2011 Neogen Corporation (Nasdaq: NEOG ) announced ... 2012, which ended Aug. 31, increased 6.5% to $45,697,000, from ... year,s revenue increase is almost entirely comprised of products available ... net income increased 3.1% from the prior year to $6,004,000, ...
... N.C. -- Copper nanowires may be coming to a little ... to drive down the costs of displaying information on cell ... build foldable electronics and improved solar cells, according to new ... have developed a technique to organize copper atoms in water ...
... ANNAPOLIS, Md., Sept. 26, 2011 PharmAthene, Inc. (NYSE ... medical countermeasures against biological and chemical threats, today announced ... Board of Directors, effective September 22, 2011. ... President and Chief Executive Officer for Nycomed U.S. which will be ...
Cached Biology Technology:Neogen Reports First Quarter Revenue and Net Income Increases 2Neogen Reports First Quarter Revenue and Net Income Increases 3Neogen Reports First Quarter Revenue and Net Income Increases 4Neogen Reports First Quarter Revenue and Net Income Increases 5Copper film could lower touch screen, led and solar cell costs 2PharmAthene Appoints Brian A. Markison to the Company's Board of Directors 2PharmAthene Appoints Brian A. Markison to the Company's Board of Directors 3
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... shown for the first time how bacteria can grow ... them the opportunity to get tremendous insights into bacteria ... also discovered the bacterial growth in chronic lung infections ... down by the immune cells. The researchers discovered the ... the bacteria, forcing the bacteria to switch to a ...
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... and misunderstandings frequently arise between individuals from different cultures. ... restrictive and another less so? A new international ... by the National Science Foundation,s Division of Behavioral and ... cultural differences and bridge the gaps between them. ...
... cause neurodegenerative prion diseases may require a genetic key, ... Chicago distinguished professor of biological sciences Susan Liebman. ... form. One prion in mammals promotes progressive neurodegenerative disorders ... how this process happens remains an open question for ...
... Calif., May 26, 2011 Epitomics, Inc. announced today ... Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use ... for Bayer HealthCare,s drug target identification and validation. ... Bayer HealthCare. This new agreement is a major expansion ...
Cached Biology News:World-wide assessment determines differences in cultures 2World-wide assessment determines differences in cultures 3Study finds 2 gene classes linked to new prion formation 2
... Molecular Imaging Systems group announces the ... Digital Imaging Systems, featuring high resolution ... fluorescence, luminescence, radiographic and chromogenic imaging ... CCD and 10x optical zoom lens ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
... for the extraction of unwanted detergent ... macromolecules, Applications: ,Reducing octyl glucoside concentration ... of pure β-adrenergic receptor and pure ... in 6 M urea/0.05 mM Tris ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: